It’s difficult to remember all aspects of your training – especially optics principles…

Chelvin Sng, Consultant Ophthalmologist, National University Hospital, Singapore

Placing the HAWK/HARRIER data in the wider context of nAMD anti-VEGF trial data.

It shouldn't be about epi-on or epi-off CXL… The focus should be on what's best for patients.

My words of wisdom on working with industry to drive ophthalmic innovation.

A beautiful image of an embryonic eye.

Can brolucizumab extend the AMD anti-VEGF treatment interval?

A recent trial shows promise for a new ocular melanoma therapeutic.

Optimizing ROP treatment by scaling back the dose.

A US research team have identified a novel enzyme that appears to play a role in disease progression.